{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T03:09:57Z","timestamp":1793761797992,"version":"4.6.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"8","funder":[{"name":"Roche Laboratories"},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We conducted a clinical trial of oral valganciclovir, a drug with in vitro activity against Kaposi sarcoma (KS)\u2013associated herpesvirus (KSHV), in classic KS. Five human immunodeficiency virus\u2013seronegative participants received valganciclovir for up to six 4-week cycles at doses used for cytomegalovirus infection. None of the study subjects showed an objective response; KS progressed in 4 subjects after 1\u20134 cycles and remained stable in 1 subject after 6 cycles. KS biopsies showed minimal lytic KSHV antigen and gene expression at baseline and no treatment-associated changes. Although valganciclovir was not active against KS in this setting, other appropriately targeted anti-herpesviral strategies may prove to be more effective.<\/jats:p>","DOI":"10.1093\/infdis\/jiq177","type":"journal-article","created":{"date-parts":[[2011,3,30]],"date-time":"2011-03-30T17:20:55Z","timestamp":1301505655000},"page":"1082-1086","source":"Crossref","is-referenced-by-count":35,"title":["Pilot Study of Oral Valganciclovir Therapy in Patients With Classic Kaposi Sarcoma"],"prefix":"10.1093","volume":"203","author":[{"given":"Susan E.","family":"Krown","sequence":"first","affiliation":[{"name":"Melanoma and Sarcoma Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk P.","family":"Dittmer","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Immunology, Lineberger Comprehensive Cancer Center, Center for AIDS Research, University of North Carolina at Chapel Hill"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethel","family":"Cesarman","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medical College, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2011,4,15]]},"reference":[{"key":"2019092512313515200_bib1","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1056\/NEJM199505043321801","article-title":"Detection of herpesvirus-like DNA sequences in KS in patients with and without HIV infection","volume":"332","author":"Moore","year":"1995","journal-title":"N Engl J Med"},{"key":"2019092512313515200_bib2","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.V86.4.1276.bloodjournal8641276","article-title":"Kaposi's Sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease","volume":"86","author":"Soulier","year":"1995","journal-title":"Blood"},{"key":"2019092512313515200_bib3","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1056\/NEJM199505043321802","article-title":"Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas","volume":"332","author":"Cesarman","year":"1995","journal-title":"N Engl J Med"},{"key":"2019092512313515200_bib4","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1172\/JCI40567","article-title":"KSHV and the pathogenesis of Kaposi sarcoma: listening to human biology and medicine","volume":"120","author":"Ganem","year":"2010","journal-title":"J Clin Invest"},{"key":"2019092512313515200_bib5","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1097\/00002030-199711000-00006","article-title":"In vitro antiviral drug sensitivity of the Kaposi's sarcoma-associated herpesvirus","volume":"11","author":"Medveczky","year":"1997","journal-title":"AIDS"},{"key":"2019092512313515200_bib6","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1172\/JCI119380","article-title":"Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy","volume":"99","author":"Kedes","year":"1997","journal-title":"J Clin Invest"},{"key":"2019092512313515200_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/00042560-200007010-00013","article-title":"Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy","volume":"24","author":"Jones","year":"2000","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2019092512313515200_bib8","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3109\/00365549409008645","article-title":"Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients","volume":"26","author":"Morfeldt","year":"1994","journal-title":"Scand J Infect Dis"},{"key":"2019092512313515200_bib9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00042560-199901010-00005","article-title":"Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS","volume":"20","author":"Robles","year":"1999","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol"},{"key":"2019092512313515200_bib10","first-page":"1787","article-title":"Foscarnet and AIDS-associated Kaposi's sarcoma","volume":"11","author":"Cordero","year":"1997","journal-title":"AIDS"},{"key":"2019092512313515200_bib11","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1086\/346159","article-title":"A pilot study of cidofovir in patients with Kaposi sarcoma","volume":"187","author":"Little","year":"2003","journal-title":"J Infect Dis"},{"key":"2019092512313515200_bib12","first-page":"153","article-title":"Matrix metalloproteinase inhibitor COL-3 in the treatment of AIDS-related Kaposi's sarcoma: a phase I AIDS malignancy consortium study","volume":"20","author":"Cianfrocca","year":"2002","journal-title":"J Clin Oncol"},{"key":"2019092512313515200_bib13","first-page":"2010","article-title":"Transcription profile of Kaposi's sarcoma-associated herpesvirus in primary Kaposi's sarcoma lesions as determined by real-time PCR arrays","volume":"63","author":"Dittmer","year":"2003","journal-title":"Cancer Res"},{"key":"2019092512313515200_bib14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1086\/588820","article-title":"Valganciclovir for suppression of human herpesvirus\u20138 replication: a randomized, double-blind, placebo-controlled, crossover trial","volume":"198","author":"Casper","year":"2008","journal-title":"J Infect Dis"},{"key":"2019092512313515200_bib15","doi-asserted-by":"crossref","article-title":"Characterization of lytic human herpesvirus-8 gene expression in Kaposi sarcoma tumor tissue and its clinical correlates.","author":"Phipps","DOI":"10.1186\/1750-9378-5-S1-A11"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jid\/article-pdf\/203\/8\/1082\/30054480\/jiq177.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T19:06:01Z","timestamp":1592420761000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/203\/8\/1082\/799917"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,4,15]]},"references-count":15,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2011,4,15]]},"published-print":{"date-parts":[[2011,4,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiq177","relation":{},"ISSN":["1537-6613","0022-1899"],"issn-type":[{"value":"1537-6613","type":"electronic"},{"value":"0022-1899","type":"print"}],"subject":[],"published-other":{"date-parts":[[2011,4,15]]},"published":{"date-parts":[[2011,4,15]]}}}